Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma

Conclusion.Prospective routine clinical genotyping in ACC can identify clinically relevant subsets of patients and is approaching financial sustainability. Demonstrating clinical utility and financial sustainability in an orphan disease (ACC) requires a multiyear and multidimensional program.Implications for Practice.Delineation of molecular profiles in adenoid cystic carcinoma (ACC) has been accomplished in the research setting; however, the ability to identify relevant patient subsets in clinical practice has not been assessed. This work presents an approach to perform integrated molecular genotyping of patients with ACC with nonresectable, recurrent, or systemic disease. It was determined that 75% of nonresectable patients harbor potentially actionable alterations and that 63% of charges are reimbursed. This report outlines that orphan diseases such as ACC require a multiyear, multidimensional program to demonstrate utility in clinical practice.

Source: The Oncologist - October 15, 2019 Category: Cancer & Oncology Authors: Julia Thierauf, Nisha Ramamurthy, Vickie Y. Jo, Hayley Robinson, Ryan P. Frazier, Jonathan Gonzalez, Macieȷ Pacula, Enrique Dominguez Meneses, Vania Nose, Valentina Nardi, Dora Dias-Santagata, Long P. Le, Derrick T. Lin, William C. Faquin, Lori J. Tags: Head and Neck Cancers, Health Outcomes and Economics of Cancer Care, Cancer Diagnostics and Molecular Pathology Source Type: research